The tumor pH was assessed using Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI) and antitumor immune responses via flow cytometry.<h4>Results</h4>We found that transdermal DYV800 significantly reduced tumor burden and improved antigen-specific CD8<sup>+</sup> T cell responses. The gene discussed is CD8A; the disease is neoplasm.